Matthias M. Engelen , Charlotte Van Edom , Andreas Verstraete , Peter Verhamme , Thomas Vanassche
{"title":"The current landscape of factor XI inhibitors","authors":"Matthias M. Engelen , Charlotte Van Edom , Andreas Verstraete , Peter Verhamme , Thomas Vanassche","doi":"10.1016/j.tru.2024.100171","DOIUrl":null,"url":null,"abstract":"<div><p>Anticoagulant therapy has always been tightly connected with bleeding risk, as two sides of the same coin. New insights in thrombosis and hemostasis prompted the development of intrinsic pathway inhibitors that promise to uncouple thrombosis and hemostasis. Treating and preventing thrombotic complications without the associated bleeding risk opens up many new possibilities for patients with an unmet need with the current anticoagulant drugs. Many candidate drugs are being investigated in phase I, II, and III clinical trials. In this review, we will introduce the new insights driving this evolution in drug development, whereafter the drugs under development and their clinical trials will be discussed.</p></div>","PeriodicalId":34401,"journal":{"name":"Thrombosis Update","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666572724000130/pdfft?md5=1ffcdc411cc22c1641e9c2bdd718dec6&pid=1-s2.0-S2666572724000130-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Thrombosis Update","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666572724000130","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Anticoagulant therapy has always been tightly connected with bleeding risk, as two sides of the same coin. New insights in thrombosis and hemostasis prompted the development of intrinsic pathway inhibitors that promise to uncouple thrombosis and hemostasis. Treating and preventing thrombotic complications without the associated bleeding risk opens up many new possibilities for patients with an unmet need with the current anticoagulant drugs. Many candidate drugs are being investigated in phase I, II, and III clinical trials. In this review, we will introduce the new insights driving this evolution in drug development, whereafter the drugs under development and their clinical trials will be discussed.
抗凝治疗一直与出血风险紧密相连，是一枚硬币的两面。对血栓形成和止血的新认识促使人们开发了内在通路抑制剂，有望解除血栓形成和止血之间的联系。治疗和预防血栓并发症，同时避免相关的出血风险，这为目前抗凝药物无法满足患者需求的患者带来了许多新的可能性。许多候选药物正在进行 I、II 和 III 期临床试验。在本综述中，我们将介绍推动这一药物开发演变的新观点，随后将讨论正在开发的药物及其临床试验。
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
